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Cystathionine  -synthase (CGS) is a transulfurication enzyme that catalyzes
the ﬁrst speciﬁc step in l-methionine biosynthesis by the reaction of O
4-succinyl-
l-homoserine and l-cysteine to produce l-cystathionine and succinate. Control-
ling the ﬁrst step in l-methionine biosythesis, CGS is an excellent potential drug
target. Mycobacterium ulcerans is a slow-growing mycobacterium that is the
third most common form of mycobacterial infection, mainly infecting people in
Africa, Australia and Southeast Asia. Infected patients display a variety of skin
ailments ranging from indolent non-ulcerated lesions as well as ulcerated lesions.
Here, the crystal structure of CGS from M. ulcerans covalently linked to the
cofactor pyridoxal phosphate (PLP) is reported at 1.9 A ˚ resolution. A second
structure contains PLP as well as a highly ordered HEPES molecule in the active
site acting as a pseudo-ligand. These results present the ﬁrst structure of a CGS
from a mycobacterium and allow comparison with other CGS enzymes. This is
also the ﬁrst structure reported from the pathogen M. ulcerans.
1. Introduction
Methionine is an essential amino acid in humans; however, in plants
and many microorganisms methionine is synthesized from both
aspartic acid and cysteine. As part of this pathway, cystathionine
 -synthase (CGS; EC 2.5.1.48) catalyzes the reaction between O
4-
succinyl-l-homoserine and l-cysteine to produce l-cystathionine and
succinate. CGS is a transferase and acts in the committed step (the
ﬁfth overall) of the biosynthesis of l-methionine. In bacteria this
mechanism is performed by the enzyme MetB, which additionally
plays roles in both selenoamino-acid metabolism and sulfur meta-
bolism. MetB is covalently linked to the cofactor pyridoxal phosphate
(PLP), similar to other members of the aspartate aminotransferase
(AAT-I) superfamily of enzymes. Similar to other CGS enzymes,
MetB forms a homotetramer, with each individual homodimer
creating two active sites (Clausen et al., 2000).
The ﬁrst CGS structure was solved for the Escherichia coli enzyme
covalently linked to the cofactor PLP (Clausen et al., 1998) and was
followed by a structure of CGS from the plant Nicotiana tabacum
also covalently linked to PLP (Steegborn et al., 1999). Steegborn and
coworkers also solved a series of structures bound to a variety of
inhibitors as potential herbicides (Steegborn et al., 2001). With the
exception of the inhibitor complexes, there are no structures of MetB
bound to any ligand or ligand-like compound at high resolution.
Mycobacterium ulcerans is the third most common form of myco-
bacterial infection behind M. tuberculosis and M. leprae and mainly
affects people from Africa, Australia and Southeast Asia (Walsh et
al., 2010). Upon infection, this slow-growing mycobacterial infection
produces painful ulcerated lesions known as Buruli ulcers. In the
early stages of treatment Buruli ulcers can be treated with antibiotics;
however, in later stages the ulcers have to be excised and in some
cases lead to amputation (Nienhuis et al., 2010). To prevent or ﬁght
this painful disease, it is of interest to obtain structural information
about potential drug targets from the organism.MetB and other PLP-containing enzymes have been identiﬁed as
prime drug targets for infectious disease organisms such as myco-
bacteria (Amadasi et al., 2007). In addition, mycobacteria prefer
using methionine as a source of sulfur, adding to the signiﬁcance of
these targets (Wheeler et al., 2005). Here, we present two structures
of the cystathionine  -synthase MetB from M. ulcerans covalently
linked to PLP and bound to the buffer molecule HEPES.
2. Methods
2.1. Protein expression and purification
The full-length M. ulcerans cystathionine  -synthase MetB (CGS)
gene encoding 388 amino acids (NCBI YP_904423.1; UniProt
A0PKT3; Pfam ID PF01053; EC 2.5.1.48) was ampliﬁed from
M. ulcerans Agy99 genomic DNA using the oligonucleotide primers
50-GGGTCCTGGTTCGATGAAGGACGATCACAAGGCGC-30
(forward) and 50-CTTGTTCGTGCTGTTTATTAGCCCAGCGCC-
TGTTTGAGGTC-30 (reverse) (Integrated DNA Technologies Inc.).
MetB was cloned into pAVA0421 vector (Alexandrov et al., 2004)
by ligation-independent cloning (LIC; Aslanidis & de Jong, 1990) to
produce a construct with an N-terminal hexahistidine tag followed
by the cleavage sequence for 3C protease (the full expression tag
sequence is MAHHHHHHMGTLEAQTQ0GPGS). The protein was
expressed in Escherichia coli BL21 (DE3) cells in 2 l auto-induction
medium (Studier, 2005) in a LEX bioreactor (Harbinger, Markham,
Ontario, Canada) at 293 K for 72 h, after which the harvested cells
were ﬂash-frozen in liquid nitrogen. The frozen cell pellet was thawed
and resuspended by vortexing in 200 ml lysis buffer [20 mM HEPES
pH 7.4, 300 mM NaCl, 5% glycerol, 30 mM imidazole, 0.5% CHAPS,
10 mM MgCl2,3 m M  -mercaptoethanol, 1.3 mg ml
 1 protease-
inhibitor cocktail (Roche, Basel, Switzerland) and 0.05 mg ml
 1
lysozyme]. The cell suspension was disrupted on ice by sonication
for 15 min with 5 s pulses at 70% amplitude using a Branson 450D
Soniﬁer (Branson Ultrasonics, Danbury, Connecticut, USA). The
soniﬁed solution was incubated with 20 ml Benzonase nuclease
(EMD Chemicals, Gibbstown, New Jersey, USA) for 40 min at room
temperature with gentle agitation. The lysate was clariﬁed by cen-
trifugation with a Sorvall RC5 at 10 000 rev min
 1 for 60 min at
277 K in an F14S Rotor (Thermo Fisher, Waltham, Massachusetts,
USA). The clariﬁed solution was syringe-ﬁltered through a 0.45 mm
cellulose acetate ﬁlter (Corning Life Sciences, Lowell, Massachusetts,
USA). The tagged MetB was puriﬁed by afﬁnity chromatography
using a HisTrap FF 5 ml column (GE Biosciences, Piscataway, New
Jersey, USA) equilibrated in binding buffer (25 mM HEPES pH 7.0,
300 mM NaCl, 5% glycerol, 30 mM imidazole, 1 mM DTT) and was
eluted with 500 mM imidazole in the same buffer.
The peak fractions containing MetB were pooled and concen-
trated. The protein concentration was determined by measuring
the absorption at 280 nm. To cleave the N-terminal afﬁnity tag, 3C
protease containing an N-terminal His tag followed by maltose-
binding protein (Alexandrov et al., 2001) was mixed with the target in
a 1:50 ratio and the mixture was dialyzed overnight at 277 K against
cleavage buffer (20 mM HEPES pH 7.6, 500 mM NaCl, 5% glycerol,
1m M TCEP). Following cleavage, there were four amino acids
(GPGS) that remained as cloning artifacts at the N-terminus of the
protein. Any uncleaved protein, 3C protease and cleaved tag were
removed by subtractive nickel-afﬁnity chromatography.
The dialyzed sample was collected and imidazole was added to
achieve a concentration of 50 mM. The sample was incubated with
5 ml Ni Sepharose 6 Fast Flow resin (GE Healthcare, Piscataway,
New Jersey, USA) for 1 h at 277 K. The sample–resin slurry was
loaded into a 20 ml Econo-Pac chromatography column (Bio-Rad,
Hercules, California, USA) and subsequently washed with 10 ml
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Table 1
Data-collection statistics.
Values in parentheses are for the highest resolution shell.
Ligands PLP PLP and HEPES
Space group P21 P21
Unit-cell parameters (A ˚ ,  ) a = 81.0, b = 106.9,
c = 100.3,   = 113.7
a = 80.9, b = 106.3,
c = 100.5,   = 113.7
Wavelength (A ˚ ) 1.5418 0.9765
Resolution range (A ˚ ) 50–1.91 (1.94–1.91) 30–1.65 (1.71–1.65)
No. of unique reﬂections 118947 (5238) 182980 (17958)
Multiplicity 6.0 (2.9) 3.8 (3.8)
Completeness (%) 98.1 (86.7) 98.0 (96.5)
Rmerge† 0.11 (0.27) 0.09 (0.44)
Mean I/ (I) 9.72 (3.70) 8.73 (2.55)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Figure 1
The overall structure of MetB from M. ulcerans.( a) In both the PLP and the PLP
and HEPES complex structures a tetramer was found similar to previous MetB
structures. Each tetramer contains two functional dimers (yellow/blue, purple/
green). Active sites facing out of the page are indicated in black, while active sites
facing into the page are indicated in red. (b) An individual dimer of MetB contains
two active sites. The main portion of the active site is made up by a pocket within
the individual monomer, with a ﬂexible loop from the second monomer closing the
pocket. The PLP moiety is shown in gray. (c) The active site of MetB covalently
linked to PLP.A tight hydrogen-bond network is created around the PLP moiety by
residues from both of the individual monomers in the homodimer. Monomer A is
indicated in blue and monomer B in yellow; hydrogen bonds are represented by
black dashed lines and range from 2.4 to 3.2 A ˚ in length. The average B factor for
PLP for the MetB–PLP structure is 14.2 A ˚ 2.wash buffer (20 mM HEPES pH 7.0, 300 mM NaCl, 40 mM imida-
zole, 1 mM TCEP, 5% glycerol); both the ﬂowthrough and the wash
were saved. Flowthrough and wash fractions from secondary afﬁnity
chromatography were pooled and concentrated using an Amicon
Ultra-15 30 kDa molecular-weight cutoff concentrator (Millipore,
Billerica, Massachusetts, USA). Size-exclusion chromatography
(SEC) was performed using a Superdex 75 HiLoad 26/60 column (GE
Healthcare, Piscataway, New Jersey, USA) that also exchanged the
protein into crystallization buffer (20 mM HEPES pH 7.0, 300 mM
NaCl, 5% glycerol, 1 mM TCEP). Peak fractions were collected and
assessed for purity by SDS–PAGE on a 4–20% Pierce Protein Gel
(Thermo Fisher) and were visualized by Coomassie staining with
InstantBlue colloidal stain (Expedeon, San Diego, California, USA).
Pure fractions were pooled, concentrated and ﬂash-frozen in liquid
nitrogen. The ﬁnal concentration was determined by spectrophoto-
metry at 280 nm and ﬁnal purity was assayed by SDS–PAGE. Samples
were ﬂash-frozen in liquid nitrogen and stored at 193 K.
2.2. Crystallization
Sitting-drop vapor-diffusion crystallization trials were set up at
289 K using the JCSG+ and PACT crystallization screens (Newman
et al., 2005). MetB stock solutions at 37 and 74 mg ml
 1 (0.4 ml) were
mixed with 0.4 ml reservoir solution and equilibrated against 100 ml
reservoir solution using 96-well Compact Jr plates from Emerald
BioSystems. Crystals grew in several conditions, but those used for
X-ray data collection and structure determination were obtained in
JCSG+ condition D9, which consists of 25.5% PEG 4000, 15%
glycerol and 170 mM ammonium sulfate. The crystals for both
structures were typically 0.2–0.3 mm in size and were yellow in color
owing to the presence of covalently linked PLP.
2.3. Data collection and structure determination
Single crystals of both MetB–PLP and MetB–PLP–HEPES were
directly frozen in liquid nitrogen utilizing the 15% glycerol from the
crystallization condition as a cryoprotectant. The MetB-PLP data set
was collected in-house using a Rigaku SuperBright FR-E+ rotating-
anode X-ray generator with Osmic VariMax HF optics and a Saturn
944+ CCDdetector (Table 1). The crystal-to-detector distance was set
to 50 cm and data were collected with 0.5  oscillations over 360  with
10 s exposure time. The overall mosaicity was 0.74 , with 118 776
measured intensities and an overall Wilson B factor of 16.2 A ˚ 2.
MetB–PLP–HEPES data were collected on Advanced Light Source
beamline 5.0.3 using a 3   3 CCD array (ADSC Q315R) detector.
The crystal-to-detector distance was set to 200 cm and data were
collected in 1.0  oscillations over 180  with 5 s exposure time. The
overall mosaicity was 0.29 , with 182 652 measured intensities and an
overall Wilson B factor of 12.4 A ˚ 2. Both data sets were reduced with
HKL-2000 (Otwinowski & Minor, 1997). The structure was solved by
molecular replacement with Phaser (McCoy et al., 2007) from the
CCP4 suite (Winn et al., 2011) using molecule B of XometC from
Xanthomonas oryzae pv. oryzae (54% identity; PDB entry 3nnp;
structural communications
1156 Clifton et al.   MetB Acta Cryst. (2011). F67, 1154–1158
Table 2
Reﬁnement and model statistics.
Values in parentheses are for the highest resolution shell.
Ligands PLP PLP and HEPES
Resolution range (A ˚ ) 50–1.91 (1.94–1.91) 30–1.65 (1.71–1.65)
Rcryst† 0.202 0.151
Rfree† 0.241 0.182
R.m.s.d. bonds (A ˚ ) 0.028 0.027
R.m.s.d. angles ( ) 2.09 2.12
Protein atoms 11010 11092
Nonprotein atoms 1625 1542
Mean B factor (A ˚ 2) 16.2 12.4
Residues in favored region (%) 98.0 98.3
Residues in allowed region (%) 1.5 1.1
Residues in disallowed region (%) 0.5 0.6
MolProbity‡ score [percentile] 1.56 [93rd] 1.14 [99th]
PDB code 3qi6 3qhx
† Rcryst =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of
the reﬂections omitted from the reﬁnement (Winn et al., 2010). ‡ Chen et al. (2010).
Figure 2
A surface electrostatics representation of MetB–PLP–HEPES. (a) The surface shows a small pocket that forms the active site between the individual monomers. (b) A side
view of the surface representation shows PLP buried deep in the active site and HEPES bound tightly in the position expected for the starting reactant O
4-succinyl-
l-homoserine.P.-T. H. Ngo, J.-K. Kim & L.-W. Kang, unpublished work) as the
search model. MetB–PLP was initially rebuilt with ARP/wARP
(Langer et al., 2008), followed by multiple rounds of reﬁnement in
REFMAC5 (Murshudov et al., 2011) and manual building in Coot
(Emsley & Cowtan, 2004). MetB–PLP–HEPES was isomorphous
to the MetB–PLP structure and could be reﬁned directly using
the phases from the previously solved MetB–PLP structure in
REFMAC5 (Murshudov et al., 2011). The ﬁnal models contained two
homodimers of MetB spanning residues Ala12–Gly388, with each
monomer covalently bound to a single PLP moiety. Both structure
models showed good geometry and correctness (Table 2) according to
analysis with MolProbity (Chen et al., 2010).
3. Results and discussion
3.1. Overall structure
MetB from M. ulcerans has 51% sequence identity to MetB from
X. oryzae pv. oryzae and 40% sequence identity to MetB from
Saccharomyces cerevisiae after alignment with ClustalW (Thompson
et al., 1994). Similar to MetB from X. oryzae and S. cerevisiae, MetB
from M. ulcerans is ordered as a homotetramer, with two individual
dimers tightly wrapped together to form two active sites per homo-
dimer (Figs. 1a and 1b; P.-T. H. Ngo, J.-K. Kim & L.-W. Kang, un-
published work; Messerschmidt et al., 2003). The overall fold of these
similar structures is also conserved. Covalently bound at the inter-
section between the two monomers is the PLP-Lys208 moiety. PLP
binds tightly to Lys208 with a covalent-bond length ranging between
1.3 and 1.4 A ˚ . The PLP cofactor is stabilized by a series of hydrogen
bonds from Gly86, Met87, Asn158, Asp183 and Ser205 from one
monomer and Tyr56 and Arg58 from the second monomer (Fig. 1c).
3.2. Product state
Cocrystallization trials with MetB–PLP and O
4-succinyl-l-homo-
serine, l-cysteine, l-cystathionine, succinate and combinations of
products and reactants proved unsuccessful, showing only the
presence of the PLP covalently bound in the active site. However, the
MetB–PLP–HEPES structure suggests that the active site is likely to
be blocked to binding of these molecules owing to the presence of a
well ordered HEPES molecule. The presence of bound HEPES in the
active site of MetB does not change the protein conformation locally
or globally (the superposition r.m.s.d.s for MetB–PLP and MetB–
PLP–HEPES were 0.134 A ˚ for molecule A, 0.136 A ˚ for molecule B,
0.151 A ˚ for molecule C, 0.141 A ˚ for molecule D and 0.15 A ˚ overall
calculated on all common C
  atoms). The only noted change is seen in
a loop consisting of residues 350–362, in which the disordered loop in
the MetB–PLP structure becomes partially ordered in the MetB–
PLP–HEPES structure.
HEPES is only found ordered in domain A; however, all the other
monomers contain a well ordered sulfate at this location, suggesting
that there may be a poorly ordered HEPES bound in each case
(Fig. 2). There is no apparent conformational change observed for the
PLP moiety in the presence or absence of HEPES. A similar series of
sulfates are found in the MetB–PLP structure; however, there is no
evidence for the presence of HEPES or any other ligand bound in the
four active sites. HEPES is bound in the active site with the sulfate
head group pointing in towards the pocket and only 3.1 A ˚ from the
"-amino group of the PLP–Lys208 moiety (Fig. 3). The HEPES
molecule is bound by a series of hydrogen bonds from the homo-
dimer, including residues Tyr111, Asn158, Ser336, Arg368 and the
PLP–Lys208 moiety of one monomer and Thr59 of the second
monomer. This tight hydrogen-bond network suggests the approx-
imate position where the starting reactant O
4-succinyl-homoserine
would be bound in the MetB active site to form the initial Michaelis
complex (Clausen et al., 1998).
4. Conclusion
We have obtained two high-resolution structures of MetB from
M. ulcerans, one covalently bound to PLP and one bound to PLP and
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Figure 3
The active site of MetB covalently linked to PLP and bound to HEPES. The tight
binding environment for the HEPES molecule is formed by a hydrogen-bonding
network created by molecules of both monomers in the homodimer. Monomer A is
indicated in blue, monomer B in yellow and HEPES in green; hydrogen bonds are
represented by black dashed lines and range from 2.4 to 3.2 A ˚ in length. The
average B factors for the PLP and HEPES molecules in the MetB–PLP–HEPES
structure are 9.1 and 15.9 A ˚ 2, respectively.
Figure 4
Electron density in the active site of MetB–PLP–HEPES. A 2Fo   Fc electron-
density map contoured at 3  (blue) clearly shows the positions of both PLP and
HEPES in the binding site of MetB.HEPES, which binds in a similar position to that expected for the
starting reactant O
4-succinyl-homoserine (Fig. 4). This structure also
represents the ﬁrst reported structure from the organism M. ulcerans.
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